CN105213299A - 含有电化学活化的次氯酸盐溶液的药物制剂 - Google Patents
含有电化学活化的次氯酸盐溶液的药物制剂 Download PDFInfo
- Publication number
- CN105213299A CN105213299A CN201510507020.2A CN201510507020A CN105213299A CN 105213299 A CN105213299 A CN 105213299A CN 201510507020 A CN201510507020 A CN 201510507020A CN 105213299 A CN105213299 A CN 105213299A
- Authority
- CN
- China
- Prior art keywords
- preparation
- saline solution
- electrochemical activation
- eye
- carrier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000004913 activation Effects 0.000 title claims abstract description 34
- 239000000825 pharmaceutical preparation Substances 0.000 title claims abstract description 15
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Chemical compound Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 title description 11
- 238000002360 preparation method Methods 0.000 claims abstract description 39
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 13
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000000460 chlorine Substances 0.000 claims abstract description 10
- 229910052801 chlorine Inorganic materials 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 9
- 230000033116 oxidation-reduction process Effects 0.000 claims abstract description 9
- 238000004140 cleaning Methods 0.000 claims abstract description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 12
- 230000003213 activating effect Effects 0.000 claims description 12
- 229920002674 hyaluronan Polymers 0.000 claims description 12
- 229960003160 hyaluronic acid Drugs 0.000 claims description 12
- 239000001913 cellulose Substances 0.000 claims description 8
- 229920002678 cellulose Polymers 0.000 claims description 8
- 229920000642 polymer Polymers 0.000 claims description 6
- 150000004676 glycans Chemical class 0.000 claims description 5
- -1 hydroxypropyl Chemical group 0.000 claims description 5
- 229920001282 polysaccharide Polymers 0.000 claims description 5
- 239000005017 polysaccharide Substances 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- 230000002421 anti-septic effect Effects 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 21
- 239000012071 phase Substances 0.000 description 13
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 10
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 description 10
- 229960001160 latanoprost Drugs 0.000 description 10
- 239000004530 micro-emulsion Substances 0.000 description 10
- 241000295644 Staphylococcaceae Species 0.000 description 8
- 230000000845 anti-microbial effect Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 238000006731 degradation reaction Methods 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 239000000645 desinfectant Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 3
- 206010013774 Dry eye Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- XTEGARKTQYYJKE-UHFFFAOYSA-M Chlorate Chemical compound [O-]Cl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-M 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000002262 irrigation Effects 0.000 description 2
- 238000003973 irrigation Methods 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000589242 Legionella pneumophila Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- IAVUPMFITXYVAF-XPUUQOCRSA-N dorzolamide Chemical compound CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 IAVUPMFITXYVAF-XPUUQOCRSA-N 0.000 description 1
- 229960003933 dorzolamide Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005868 electrolysis reaction Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229940115932 legionella pneumophila Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- LWXVCCOAQYNXNX-UHFFFAOYSA-N lithium hypochlorite Chemical compound [Li+].Cl[O-] LWXVCCOAQYNXNX-UHFFFAOYSA-N 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 229960004605 timolol Drugs 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L12/00—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
- A61L12/08—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L12/00—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
- A61L12/08—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
- A61L12/10—Halogens or compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L12/00—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
- A61L12/08—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
- A61L12/10—Halogens or compounds thereof
- A61L12/107—Hypohalites; Active halogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/0005—Other compounding ingredients characterised by their effect
- C11D3/0078—Compositions for cleaning contact lenses, spectacles or lenses
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/395—Bleaching agents
- C11D3/3956—Liquid compositions
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D2111/00—Cleaning compositions characterised by the objects to be cleaned; Cleaning compositions characterised by non-standard cleaning or washing processes
- C11D2111/40—Specific cleaning or washing processes
- C11D2111/46—Specific cleaning or washing processes applying energy, e.g. irradiation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Wood Science & Technology (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Eyeglasses (AREA)
- Apparatus For Disinfection Or Sterilisation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95203507P | 2007-07-26 | 2007-07-26 | |
| US60/952,035 | 2007-07-26 | ||
| US98818107P | 2007-11-15 | 2007-11-15 | |
| US60/988,181 | 2007-11-15 | ||
| CN200880025290.8A CN101778621B (zh) | 2007-07-26 | 2008-07-28 | 含有电化学活化的次氯酸盐溶液的药物制剂 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200880025290.8A Division CN101778621B (zh) | 2007-07-26 | 2008-07-28 | 含有电化学活化的次氯酸盐溶液的药物制剂 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105213299A true CN105213299A (zh) | 2016-01-06 |
Family
ID=40239573
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510507020.2A Pending CN105213299A (zh) | 2007-07-26 | 2008-07-28 | 含有电化学活化的次氯酸盐溶液的药物制剂 |
| CN200880025290.8A Expired - Fee Related CN101778621B (zh) | 2007-07-26 | 2008-07-28 | 含有电化学活化的次氯酸盐溶液的药物制剂 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200880025290.8A Expired - Fee Related CN101778621B (zh) | 2007-07-26 | 2008-07-28 | 含有电化学活化的次氯酸盐溶液的药物制剂 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20100266710A1 (enExample) |
| EP (1) | EP2178501B1 (enExample) |
| JP (1) | JP5872159B2 (enExample) |
| KR (2) | KR101733723B1 (enExample) |
| CN (2) | CN105213299A (enExample) |
| AU (1) | AU2008280437B2 (enExample) |
| CA (1) | CA2694929C (enExample) |
| ES (1) | ES2671372T3 (enExample) |
| RU (1) | RU2554802C2 (enExample) |
| WO (1) | WO2009013019A2 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111511210A (zh) * | 2017-11-27 | 2020-08-07 | 萨尼克斯特姆股份有限公司 | 提供消毒泡沫的制剂 |
| CN112805064A (zh) * | 2018-07-12 | 2021-05-14 | Azad药物股份公司 | 电化学活化的盐溶液 |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2422792A1 (de) | 2010-08-26 | 2012-02-29 | Caliopa AG | Elektrochemisch aktivierte Lösung auf Wasserbasis und Verwendung der Lösung |
| SI2374762T1 (sl) | 2010-03-31 | 2013-05-31 | Caliopa Ag | Postroj in postopek za tvorjenje elektrokemično aktivirane raztopine |
| BR112012024879A2 (pt) * | 2010-03-31 | 2019-09-24 | Caliopa Ag | solução à base de água ativada eletroquimicamente e uso da solução |
| EP2431056A1 (de) * | 2010-09-16 | 2012-03-21 | Caliopa AG | Pharmazeutische Zusammensetzung, enthaltend elektrochemisch aktivierte Salzlösung |
| EP2543359A1 (de) * | 2011-07-08 | 2013-01-09 | Caliopa AG | Gel zur Verwendung in einem Wundbehandlungsmittel |
| EP2567689A1 (en) * | 2011-09-12 | 2013-03-13 | Visiotact Pharma | Ophthtalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid |
| RU2016151360A (ru) * | 2011-09-16 | 2018-11-15 | ЗУРЕКС ФАРМАГРА, ЭлЭлСи | Системы и способы производства гермицидных композиций |
| US10617716B2 (en) * | 2014-12-16 | 2020-04-14 | Urgo Us, Inc. | Hypochlorous acid formulations and methods for treating skin conditions |
| CN109843288A (zh) * | 2016-10-21 | 2019-06-04 | 狮王株式会社 | 眼科用制剂和眼科用药 |
| EP3919047A1 (en) * | 2020-06-03 | 2021-12-08 | AZAD Pharma AG | Microemulsion for the treatment of dry eye syndrome |
| EP4225271A4 (en) * | 2020-10-12 | 2024-10-23 | The Regents Of The University Of Colorado, A Body Corporate | COMPOSITIONS AND METHODS FOR LOWERING INTRACRANIAL PRESSURE BY INTRANASAL ADMINISTRATION OF AN AGENT |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006102681A2 (en) * | 2005-03-23 | 2006-09-28 | Oculus Innovative Sciences, Inc. | Method of treating skin ulcers using oxidative reductive potential water solution |
| CN1845877A (zh) * | 2003-12-30 | 2006-10-11 | 奥古露丝创新科学公司 | 氧化还原电势水溶液、生产它的方法和使用它的方法 |
| US20070196434A1 (en) * | 2006-01-20 | 2007-08-23 | Oculus Innovative Sciences, Inc. | Methods of preventing or treating sinusitis with oxidative reductive potential water solution |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5693337A (en) * | 1994-07-13 | 1997-12-02 | Wakamoto Pharmaceutical Co., Ltd. | Stable lipid emulsion |
| JPH10236961A (ja) * | 1997-02-25 | 1998-09-08 | Nobel Igaku Kenkyusho:Kk | 電解酸性水を用いた眼科用剤 |
| WO2000024431A1 (en) * | 1998-10-23 | 2000-05-04 | Radical Waters Ip (Pty) Limited | Method for applying bactericidal solutions |
| WO2000033757A1 (en) * | 1998-12-09 | 2000-06-15 | Advanced H¿2?O Inc. | A system for decontamination of dental unit waterlines using electrolyzed water |
| RU2148027C1 (ru) * | 1999-02-01 | 2000-04-27 | Бахир Витольд Михайлович | Способ получения дезинфицирующего раствора - нейтрального анолита анд |
| US7393522B2 (en) * | 2000-01-12 | 2008-07-01 | Novabay Pharmaceuticals, Inc. | Physiologically balanced, ionized, acidic solution and methodology for use in wound healing |
| WO2001056616A2 (en) * | 2000-02-04 | 2001-08-09 | Radical Waters Ip (Pty) Limited | Dental equipment and method of operating such equipment |
| RU2180605C1 (ru) * | 2000-07-24 | 2002-03-20 | Завод "Автоматика" | Способ внутриушной ультразвуковой терапии хронических средних отитов |
| DE60326226D1 (de) * | 2002-03-21 | 2009-04-02 | Cayman Chemical Co | Prostaglandin f2 alpha analoga in kombination mit einem antimikrobiellen mittel zur behandlung von glaukom |
| US20040191332A1 (en) * | 2003-03-27 | 2004-09-30 | Allergan, Inc. | Preserved ophthalmic compositions |
| US20050196462A1 (en) * | 2003-12-30 | 2005-09-08 | Oculus Innovative Sciences, Inc. | Topical formulation containing oxidative reductive potential water solution and method for using same |
| CA2586074C (en) * | 2004-11-09 | 2013-07-23 | Novagali Pharma Sa | Ophthalmic oil-in-water type emulsion with stable positive zeta potential |
| JP5186217B2 (ja) * | 2005-11-28 | 2013-04-17 | 千寿製薬株式会社 | Ｐｐａｒアゴニスト含有医薬 |
-
2008
- 2008-07-28 CA CA2694929A patent/CA2694929C/en not_active Expired - Fee Related
- 2008-07-28 EP EP08801496.4A patent/EP2178501B1/en active Active
- 2008-07-28 JP JP2010517329A patent/JP5872159B2/ja not_active Expired - Fee Related
- 2008-07-28 KR KR1020157020110A patent/KR101733723B1/ko not_active Expired - Fee Related
- 2008-07-28 WO PCT/EP2008/006193 patent/WO2009013019A2/en not_active Ceased
- 2008-07-28 AU AU2008280437A patent/AU2008280437B2/en not_active Ceased
- 2008-07-28 CN CN201510507020.2A patent/CN105213299A/zh active Pending
- 2008-07-28 RU RU2010107043/15A patent/RU2554802C2/ru active
- 2008-07-28 KR KR1020107003555A patent/KR101633449B1/ko not_active Expired - Fee Related
- 2008-07-28 ES ES08801496.4T patent/ES2671372T3/es active Active
- 2008-07-28 CN CN200880025290.8A patent/CN101778621B/zh not_active Expired - Fee Related
- 2008-07-28 US US12/670,513 patent/US20100266710A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1845877A (zh) * | 2003-12-30 | 2006-10-11 | 奥古露丝创新科学公司 | 氧化还原电势水溶液、生产它的方法和使用它的方法 |
| WO2006102681A2 (en) * | 2005-03-23 | 2006-09-28 | Oculus Innovative Sciences, Inc. | Method of treating skin ulcers using oxidative reductive potential water solution |
| US20070196434A1 (en) * | 2006-01-20 | 2007-08-23 | Oculus Innovative Sciences, Inc. | Methods of preventing or treating sinusitis with oxidative reductive potential water solution |
Non-Patent Citations (2)
| Title |
|---|
| 陈祖基: "《眼科临床药理学》", 31 October 2002, 化学工业出版社 * |
| 黄铭西，等: "《消毒与有害生物防制技术》", 31 July 2005, 湖北科学技术出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111511210A (zh) * | 2017-11-27 | 2020-08-07 | 萨尼克斯特姆股份有限公司 | 提供消毒泡沫的制剂 |
| CN112805064A (zh) * | 2018-07-12 | 2021-05-14 | Azad药物股份公司 | 电化学活化的盐溶液 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009013019A2 (en) | 2009-01-29 |
| WO2009013019A3 (en) | 2009-04-09 |
| US20100266710A1 (en) | 2010-10-21 |
| CN101778621A (zh) | 2010-07-14 |
| AU2008280437B2 (en) | 2012-11-29 |
| RU2554802C2 (ru) | 2015-06-27 |
| EP2178501B1 (en) | 2018-05-02 |
| CA2694929A1 (en) | 2009-01-29 |
| CN101778621B (zh) | 2015-09-09 |
| RU2010107043A (ru) | 2011-09-10 |
| ES2671372T3 (es) | 2018-06-06 |
| KR101733723B1 (ko) | 2017-05-10 |
| EP2178501A2 (en) | 2010-04-28 |
| KR20150093244A (ko) | 2015-08-17 |
| CA2694929C (en) | 2016-10-18 |
| KR101633449B1 (ko) | 2016-06-24 |
| AU2008280437A1 (en) | 2009-01-29 |
| KR20100051817A (ko) | 2010-05-18 |
| JP5872159B2 (ja) | 2016-03-01 |
| JP2010534629A (ja) | 2010-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105213299A (zh) | 含有电化学活化的次氯酸盐溶液的药物制剂 | |
| EP2331066B1 (en) | Mucomimetic compositions and uses therefore | |
| TW200942262A (en) | Aqueous pharmaceutical compositions containing borate-polyol complexes | |
| JP2010534629A5 (enExample) | ||
| AU2021212055A1 (en) | Antimicrobial compositions containing polyquaternium | |
| CN101674848A (zh) | N-卤代氨基酸制剂及用于清洁和消毒的方法 | |
| JP2004315472A (ja) | 眼科用製剤、点眼液、人工涙液、コンタクトレンズケアー用品、洗眼液、および眼軟膏 | |
| US20110257125A1 (en) | Mucomimetic compositions and uses therefore | |
| CA2758858C (en) | Aqueous ophthalmic compositions containing anionic therapeutic agents | |
| TW200427661A (en) | Aqueous solution of olanexidine, method of preparing the aqueous solution, and disinfectant | |
| JPWO2005072727A1 (ja) | 点眼剤組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160106 |
|
| RJ01 | Rejection of invention patent application after publication |